Antibody-Bound Nanoparticles via Segmented Self-Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the capability to precisely form ordered and structurally homogeneous antibody-bound nanoparticle structures for therapeutic and diagnostic applications.
Innovation Solution
Development of particles comprising polypeptide polymers with specific amino acid sequences and Tie2 receptor antibodies or α-TNFRSF antibodies fused with Fc domains, which non-covalently bind to form dihedral, tetrahedral, octahedral, or icosahedral symmetry structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to form antibody-bound nanoparticle structures, then the structures can be formed with some degree of complexity, but the precision and structural homogeneity of the nanoparticle structures cannot be achieved
Solution Approach 1:
The patent divides the nanoparticle structure into discrete geometric units (triangles, squares, pentagons, hexagons) that can be independently formed and then assembled. Each unit is defined by specific numbers of antibodies and Fc-binders arranged in precise configurations, allowing modular construction of complex polyhedral structures with controlled precision.
Solution Approach 2:
The patent applies different structural configurations to different regions of the nanoparticle. Each geometric unit (face, edge, vertex) has specific local properties defined by the number and arrangement of antibodies and Fc-binders. This local differentiation enables precise control over the overall structural homogeneity while maintaining geometric complexity.
2Strength
If antibodies are oligomerized to enhance avidity and receptor clustering, then the binding strength is improved, but the ability to form ordered and structurally homogeneous structures is lost
Solution Approach 1:
The patent uses asymmetric arrangements of antibodies and Fc-binders within each geometric unit to create specific binding orientations. The Fc-domains are positioned at vertices with specific coordination numbers (3, 4, or 5), creating asymmetric but highly ordered structures that maintain both binding strength and structural homogeneity through controlled asymmetry rather than random oligomerization.
Solution Approach 2:
The patent employs dynamic self-assembly processes where antibodies and Fc-binders spontaneously organize into predetermined geometric structures. The system transitions from individual components to ordered oligomeric structures through controlled self-organization, maintaining structural homogeneity while achieving the desired avidity and receptor clustering.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These structures enhance signaling pathways, such as AKT and ERK1/2 phosphorylation, and are effective in treating vascular dysfunction-related diseases and tumors by forming precise, higher-order, cage-like structures.
Implementation Method 1
each Tie2 antibody or dimer in the plurality is (A) non-covalently bound via the first Fc domain to one polypeptide monomer chain of a first polymer, and (B) non-covalently bound via the second Fc domain to one polypeptide monomer of a second polymer
Data Source
AI summary
Antibody particles are disclosed comprising polypeptides comprising an (Fc) binding domain, a helical polypeptide monomer, and an oligomer domain, and either Tie2 antibodies or dimers, or tumor necrosis factor receptor superfamily antibodies, and uses thereof.